ENA Respiratory is a clinical-stage pharmaceutical company developing immune enhancers for the prevention of complications associated with respiratory viral infections in at-risk populations.
The company’s lead product is INNA-051, a first-in-class TLR2/6 agonist developed as a convenient, self-administered nasal product with a weekly dosing regimen.
INNA-051 works by priming and boosting the body’s innate immune response – the natural first line of defence – at the primary entry site of viral respiratory infections in the upper respiratory tract. This leads to accelerated viral clearance and reduced virus dissemination to the lower airways (lungs).
INNA-051 clinical development is led by an experienced team of clinicians and drug developers who have a deep understanding of respiratory diseases and a track record of bringing multiple new respiratory treatments to the US and other markets.
We are focused on improving the lives of vulnerable populations at risk of complications from respiratory viral infections and minimising the burden on the health care system.
INNA-051 is effective against multiple respiratory viruses and has demonstrated a favourable safety profile that supports seasonal prophylactic use and a fast onset of action with a durable response to enable weekly dosing.
ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051
ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral